Kidney Transplantation After Teclistamab-Induced Remission in Relapsed Multiple Myeloma (KIDNEY WEEK 2026) - Oct 2, 2026 - Abstract #FR-PO1277; Pres time: Oct 23, 2026; 10:00 AM - 12:00 PM; Location: Exhibit Hall A, Convention Center; "He received bortezomib-based induction followed by autologous stem cell transplant in 2013 and lenalidomide maintenance until 2016. After relapse in 2017, he was treated with daratumumab/lenalidomide/dexamethasone...He received carfilzomib/cyclophosphamide/dexamethasone from 2019-2022...In August 2025, he underwent a living-related kidney transplantation with basiliximab induction and tacrolimus, mycophenolate, and prednisone maintenance. Post-transplant course included rhinovirus infection, low level BK viremia, Citrobacter UTI, and mycophenolate intolerance for which he was switched to azathioprine...Transplant centers should consider the improved outcomes of patients with ESRD from MM achieving complete response with these newer agents. Multidisciplinary discussions are required for candidacy discussions and post-transplant management."
Clinical • Acute Kidney Injury • Amyloidosis • Chronic Kidney Disease • Hematological Malignancies • Infectious Disease • Multiple Myeloma • Nephrology • Renal Disease • Transplantation
|
|
Divya Ravi; Jeffrey L. Wolf; Thomas Martin; Allison B. Webber
|